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Clinicians  have  widely  adopted  drug-eluting  stents  (DES)  over  bare-metal  stents  (BMS)
for  percutaneous  revascularization  (PCI)  in  patients  with  coronary  artery  disease,  because
DES  decrease  the  risk  for  in-stent  coronary  restenosis  and  repeated  revascularization  [1,2].
Moreover,  a  landmark  trial  has  shown  that  second-generation  DES  reduce  the  rates  of  stent
thrombosis  compared  with  ﬁrst-generation  DES  [3].  Research  is  being  conducted  to  further
improve  the  new  stents,  the  bioabsorbable  stents  being  the  latest  proof  of  this  continuing
process.  Barragan  et  al.  were  the  pioneers  in  the  ﬁeld  of  dual  antiplatelet  therapy  (DAPT)
after  BMS  placement  [4];  they  were  convinced  that  aspirin  plus  the  only  thienopyridine
available  at  the  end  of  the  last  century  —  namely,  ticlopidine  —  were  together  the  best
therapy  after  DES  placement.  Indeed,  we  have  to  keep  in  mind  that  stent  thrombosis  was
at  this  time  not  only  dramatic,  as  it  is  nowadays,  but  also  much  more  frequent.  After
the  ﬁrst  publication  suggesting  the  efﬁcacy  of  DAPT,  Schömig  et  al.  clearly  demonstrated
the  beneﬁt  of  such  therapy  in  reducing  the  risk  of  stent  thrombosis  [5].  Interestingly,  in
the  ﬁrst  publications  leading  to  the  approval  of  DES,  involving  the  sirolimus-eluting  stent
and  the  paclitaxel-eluting  stent,  the  duration  of  DAPT  was  rather  short,  3  and  6  months,
respectively.  Then,  ﬁndings  from  observational  studies  suggested  that  in  patients  who  had
undergone  DES  placement,  discontinuation  of  DAPT  resulted  in  an  elevated  risk  of  acute
stent  thrombosis.  In  2006,  the  so-called  ‘‘ﬁrestorm’’  at  the  European  Society  of  Cardiology
(ESC)  Congress,  held  in  Barcelona,  reached  the  cardiology  world.  The  possible  increase  in
the  rate  of  late  stent  thrombosis  with  DES  compared  with  BMS  became  a  real  nightmare
for  cardiologists.  The  advent  of  a  sudden  unexpected  late  stent  thrombosis  was  a  major
concern.  Imagine  a  young,  stable  patient  with  a  signiﬁcant  stenosis  in  a  lateral  artery
in  whom  a  DES  was  successfully  implanted.  This  patient,  now  angina  free,  dies  suddenly
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 months  after  stopping  treatment  with  clopidogrel.  The  fact
hat  this  patient  could  have  died  due  to  a  stent  thrombosis
elated  to  clopidogrel  discontinuation  leads  comprehen-
ively  to  many  questions,  including  the  duration  of  DAPT.
he  old  question  about  a  possible  rebound  after  cessation
f  antithrombotic  drugs  emerges  with  clopidogrel.  A  cluster-
ng  of  adverse  events  in  the  initial  3  months  after  stopping
lopidogrel  among  both  medically  treated  and  PCI-treated
atients  with  acute  coronary  syndromes  was  observed  [6].
herefore,  because  stent  thrombosis  was  frequently  associ-
ted  with  myocardial  infarction,  and  sometimes  with  death,
any  clinicians  responded  to  these  events  by  suggesting
ndeﬁnite  treatment  with  DAPT,  despite  the  fear  of  bleeding.
mong  these  clinicians  were  recognized  experts  in  the  ﬁeld.
herefore,  in  everyday  clinical  practice,  about  half  of  the
atients  who  received  a  DES  also  received  DAPT  for  much
ore  than  1  year.  The  optimal  duration  of  DAPT  after  DES
mplantation  was  highly  controversial.  Even  the  recommen-
ations  laid  out  in  guidelines  from  Europe  and  North  America
iverged  slightly  [7,8],  DAPT  is  currently  recommended  for
t  least  6—12  months  after  implantation  of  a  DES.
The  question  on  the  optimal  duration  of  DAPT  after
ES  placement  is  not  only  a  theoretical  question.  For  each
atient,  the  clinician  has  to  make  a  decision.  Therefore,  it  is
ot  surprising  that  many  clinical  trials  have  been  undertaken
o  try  to  evaluate  this  issue.  In  2012,  the  ﬁrst  meta-analysis
f  four  randomized  trials  comparing  the  clinical  effect  of
xtended  DAPT  after  PCI  in  the  DES  era  was  published  [9].
our  trials  have  indeed  compared  extended  DAPT  (12  to
4  months)  versus  shorter  durations  (3  to  12  months).  A
otal  of  8158  patients  were  available  for  this  analysis.  The
uthors  concluded  that  extension  of  DAPT  duration  after  PCI
ay  increase  the  risk  of  bleeding  without  reducing  the  risk
f  ischaemic  events.  They  acknowledged  that  these  results
ould  need  corroboration  in  ongoing  large  trials.  These
esults  were  favorably  accepted,  particularly  in  Europe,
nd  by  interventional  cardiologists.  It  is  understandable
hat  if  DES  would  need  very  long-term  treatment  with  DAPT,
mplantation  of  these  stents  would  be  more  problematic.
hen,  other  studies  have  shown  no  signiﬁcant  differences  in
et  clinical  outcome  between  6  and  12  months  or  24  months
f  clopidogrel  therapy  after  DES  implantation.  The  new  turn-
ng  point  was  the  publication  of  the  DAPT  study,  the  largest
tudy  on  this  topic,  powered  to  detect  differences  in-stent
hrombosis  and  major  cardiac  adverse  cardiovascular  and
erebrovascular  events  (MACCE)  with  or  without  extended
APT  [10].  A  total  of  9961  patients  free  from  myocardial
nfarction,  stroke,  repeat  coronary  revascularization,  stent
hrombosis,  and  moderate  or  severe  bleeding  and  compliant
fter  12  months  of  treatment  with  clopidogrel  or  prasugrel
nd  aspirin  following  a  DES  implantation,  were  randomly
ssigned  to  continue  thienopyridine  treatment  or  to  receive
lacebo.  In  this  important  study,  DAPT  therapy  beyond
 year  after  placement  of  a  DES,  versus  aspirin  therapy
lone,  signiﬁcantly  reduced  the  risk  of  stent  thrombosis
nd  MACCE  but  was  associated  with  an  increased  risk  of
leeding.  The  rate  of  stent  thrombosis  decreased  from  1.4%
o  0.4%  with  DAPT,  and  the  rate  of  myocardial  infarction
ecreased  from  4.1%  to  2.4%.  Surprisingly,  the  rate  of  death
rom  any  cause  increased  from  1.5%  to  2.0%  with  DAPT
P  =  0.05).  Counter  to  what  has  been  reported,  in  the  DAPT
tudy,  the  use  of  thienopyridine  beyond  1  year  reduced  the
n
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isks  of  both  outcomes  across  all  stent  types.  A  few  months
ater,  the  ﬁndings  from  the  PEGASUS  trial  were  released.
he  PEGASUS  trial  was  designed  to  evaluate  the  potential
eneﬁt  of  DAPT  (ticagrelor  and  aspirin)  beyond  1  year  after
 myocardial  infarction,  with  or  without  stent  implantation
11]. More  than  21,000  patients  were  randomized  between
icagrelor  90  mg  twice  daily,  ticagrelor  60  mg  twice  daily  or
lacebo,  on  a background  of  aspirin.  Treatment  with  tica-
relor  signiﬁcantly  reduced  the  risk  of  cardiovascular  death,
yocardial  infarction  or  stroke.  However,  once  again,  the
ates  of  TIMI  major  bleeding  were  higher  with  ticagrelor
han  with  placebo.  Both  the  DAPT  trial  and  the  PEGASUS
rial  have  shown  that  prolonged  P2Y12-receptor  blockade
educed  the  rate  of  ischaemic  events  and  increased  the
ate  of  bleeding  events  among  patients  with  coronary
isease.  Then,  several  meta-analyses  were  performed
rying  to  combine  evidence  regarding  the  optimum  duration
f  DAPT.  The  authors  of  one  such  analysis  concluded  that
xtended  DAPT  is  associated  with  approximately  eight
ewer  myocardial  infarctions  per  1000  treated  patients  per
ear,  but  with  six  more  major  bleeding  events,  compared
ith  a  shorter  duration  of  DAPT  [12].
With  regards  to  this  controversial  question,  the  recently
ublished  OPTIDUAL  trial  aimed  to  demonstrate  the  supe-
iority  of  extended  DAPT  up  to  48  months  compared  with
2  months  of  DAPT  in  reducing  the  rate  of  net  adverse
linical  events,  a  composite  of  death,  myocardial  infarc-
ion,  stroke  and  major  ISTH  bleeding  [13].  At  12  ±  3  months
fter  DES  implantation,  patients  who  were  receiving  DAPT
clopidogrel  plus  aspirin)  and  who  had  remained  free  of
ajor  cardiovascular  and  cerebrovascular  events  or  major
leeding  were  randomly  assigned  (1:1)  to  receive  clopi-
ogrel  75  mg  daily  (extended  DAPT  group)  for  a  further
6  additional  months  (total  treatment  duration  with  DAPT:
8  ±  3  months)  or  to  discontinue  clopidogrel  (aspirin  group).
hile  the  trial  did  not  demonstrate  the  superiority  of
xtended  DAPT,  there  was  a  borderline  but  non-statistically
igniﬁcant  reduction  in  the  post-hoc  ischaemic  outcomes  (a
omposite  of  death,  myocardial  infarction  and  stroke)  with
xtended  DAPT.  With  extended  DAPT  up  to  48  months  after
ES  placement,  there  was  a  lower  rate  of  ischaemic  out-
omes  that  appeared  related  to  consistently  lower  rates  of
ll  ischaemic  components  (risk  reduction  > 30%).  Interest-
ngly,  there  was  no  apparent  increase  in  all-cause  mortality
nd  major  bleeding.  The  rates  of  major  ISTH  bleeding  were
dentical  in  both  groups  (2.0%).  Therefore,  the  OPTIDUAL
esults  are  consistent  with  the  ﬁndings  from  the  DAPT  trial
egarding  the  value  of  prolonging  DAPT  after  DES  placement.
t  appears  that  OPTIDUAL  selected  a population  at  low  risk
f  bleeding,  particularly  as  DAPT  is  associated  with  a  greater
isk  of  bleeding  in  the  ﬁrst  year  after  initiating  therapy.
In  everyday  clinical  practice,  the  decision  on  the  opti-
um  duration  of  DAPT  for  a  given  patient  remains  difﬁcult
o  determine.  The  physician  has  to  identify  who  will  ben-
ﬁt  from  prolonged  DAPT  for  protection  against  ischaemic
omplications,  with  the  least  hazard  of  bleeding.  Undoubt-
dly,  better  risk  stratiﬁcation  strategies  —  to  balance  the
isk  of  ischaemic  events  against  those  of  bleeding  —  are
eeded  to  assess  the  need  for  long-term  treatment  with
ntiplatelet  agents.  The  other  perspectives  for  ﬁnding  a  bet-
er  outcome  with  extended  DAPT  after  DES  placement  could
e  new  antiplatelet  agents,  such  as  the  protease-activated
ES  
[
[
[The  saga  of  the  duration  of  dual  antiplatelet  therapy  after  D
receptor  1  inhibitors  (e.g.  vorapaxar  or  others),  or  per-
haps  a  single  antiplatelet  agent  without  aspirin,  which  could
improve  the  safety  while  preserving  ischaemic  outcomes
beneﬁt.  What  is  clear:  the  saga  of  antiplatelet  therapy  after
DES  is  not  yet  ﬁnished.
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